Despite growing demand, varied reimbursement and regulatory policies could impede market momentum
LONDON - 17th July 2012 - The European genetic testing and screening services market is poised to be driven by the increasing availability of tests covering a wider range of disease areas, paralleled by a rapidly expanding pool of potential consumers. Testing for genetic diseases has swiftly moved from the laboratory into medical practice. In this process, issues related to quality have not received adequate attention.
New analysis from Frost & Sullivan (http://www.drugdiscovery.frost.com), European Genetic Testing and Screening Services Market, finds that the market earned revenues of $896.2 million in 2011 and estimates this to reach $1908.8 million in 2018. The research covers diagnostic testing/screening, relationship testing and predictive testing. Heightened awareness, primarily due to widespread genetic counselling groups and the availability of direct-to-consumer (DTC) tests will boost market prospects.
"Demand for genetic testing will receive further impetus when accompanied by consultation, counselling physician's advice and proper reimbursement," noted Frost & Sullivan Senior Research Analyst Divyaa Ravishankar. "There is a rising interest in predictive testing, which is seen as the highest growth area within genetic testing."
Genetic testing and screening are the next big focus in molecular diagnostics. The molecular diagnostics market in Western Europe is worth $1,352.4 million, and genetic testing contributed almost 66 per cent of its revenue in 2011.
The cost of sequencing a genome is reducing, with new, efficient next-generation sequencing platforms. This will create fierce competition for faster turn-around times and will have a positive impact on the genetic testing and screening market.
Varying reimbursement procedures across Europe, however, loom as a major concern to market participants. When samples are being shipped across international boundaries, inadequate reimbursement can result in uneven access to genetic testing services.
"There are potential gaps that exist in the regulatory and normative framework which need to be addressed," cautioned Ravishankar. "Currently, there is no legal requirement on quality assurance, specifically for diagnostic laboratories in different member states of the EU."
Obtaining accreditation and certification is entirely voluntary. Only a few European labs have obtained them. Moreover, the definitions of ‘accreditation' and ‘certification' are still not universally accepted in EU member states.
"Defining a framework for reimbursement related to cross-border exchange of samples for genetic testing and data is critical," advised Ravishankar. "Proper rules should be framed for reimbursement when samples are tested in other nations; pan-European co-operation will be essential to streamlining cross-border shipping."
If you are interested in more information on this study, please send an e-mail with your contact details to Janique Morvan, Corporate Communications, at email@example.com.
European Genetic Testing and Screening Services Market is part of the Clinical Diagnostics Growth Partnership Services programme, which also includes research in the following markets: Western European In Vitro Diagnostics (IVD) Market, European Molecular Diagnostics Market and Strategic Analysis of the European Stem Cell Research Tools Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
European Genetic Testing and Screening Services Market
Corporate Communications – Europe
P: +33 (0)1 42 81 20 37
M: +33 (0)6 79 22 41 42